Psychopharmacology

, Volume 125, Issue 1, pp 50–56 | Cite as

Age-related decline in central cholinergic function demonstrated with scopolamine

  • P. N. Tariot
  • S. V. Patel
  • C. Cox
  • R. E. Henderson
Original Investigation

Abstract

Scopolamine hydrobromide was administered intravenously to 23 normal subjects (40–89 years) in doses of 0.1 mg, 0.25 mg, and 0.5 mg, in a doubleblind, placebo-controlled, random-order fashion. The effects of scopolamine, as compared to placebo, were assessed using a comprehensive cognitive test battery, as well as behavioral and physiological measures. Scopolamine produced the expected dose-dependent impairments in most of the cognitive functions assessed. Behavioral and physiological measures were also affected, but only minimally. More importantly, there was a significant overall correlation between age and scopolamine-impaired performances on psychomotor speed, short-term recall, visual tracking speed, visuo-motor coordination, and sequencing ability. There was, however, some inter-individual variability in this phenomenon. The results provide further evidence that cholinergically mediated cognitive functions show an increased sensitivity to scopolamine with age, albeit with heterogeneity that bears further investigation.

Key words

Scopolamine Aging Cognition Memory 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen SJ, Benton JS, Goodhardt MJ et al. (1983) Biochemical evidence of selective nerve cell changes in the normal aging human and rat brain. J Neurochem 41:256–265PubMedGoogle Scholar
  2. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417Google Scholar
  3. Battig W, Montague N (1969) Category norms for verbal items in 56 categories. J Exp Psychol Monogr 80:1–43Google Scholar
  4. Beatty WW, Butters N, Janowsky DS (1986) Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neurol Biol 45:196–211CrossRefGoogle Scholar
  5. Benton AL (1963) The revised visual retention test: clinical and experimental applications. The Psychological Corporation, New YorkGoogle Scholar
  6. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modeling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26:685–700CrossRefPubMedGoogle Scholar
  7. Buschke H (1973) Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 12:543–550CrossRefGoogle Scholar
  8. Caine ED, Weingartner H, Ludlow DL, Cudahy EA, Wehry S (1981) Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology 74:74–80CrossRefPubMedGoogle Scholar
  9. Crow TJ, Grove-White IG (1973) An analysis of the learning deficit following hyoscine administration to man. Br J Pharmacol 49: 322–327PubMedGoogle Scholar
  10. Curran HV, Schifano F, Lader M (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103:83–90PubMedGoogle Scholar
  11. Decker MW (1987) The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res Rev 12:423–438CrossRefGoogle Scholar
  12. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system: a relationship to aging? Arch Neurol 30:113–121PubMedGoogle Scholar
  13. Dunne M, Hartley LR (1986) Scopolamine and the control of attention in humans. Psychopharmacology 89:94–97Google Scholar
  14. Esheer D, Schrock B (1986) Attention. In: Haney HJ (ed) Experimental techniques in human neuropsychology. Oxford University Press, New YorkGoogle Scholar
  15. Fleiss JL (1986) The design and analysis of clinical experiments. Wiley, New YorkGoogle Scholar
  16. Flicker C, Serby M, Ferris SH (1990) Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243–250Google Scholar
  17. Flicker C, Ferris SH, Serby M (1992) Hypersensitivity to scopolamine in the elderly. Psychopharmacology 107:437–441PubMedGoogle Scholar
  18. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  19. Frith CD, Richardson JTE, Samuel M, Crow TM, McKenna PJ (1984) The effects of intravenous diazepam and hyoscine upon human memory. Q J Exp Psychol 36A:133–144Google Scholar
  20. Gibson G, Peterson C, Jenden DJ (1981) Brain acetylcholine declines with senescence. Science 213:674–676PubMedGoogle Scholar
  21. Hachinski VC, Iliff LD, Zilhka E, KuBoulary GH, McAllister VL, Marshall J, Russell RWR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637PubMedGoogle Scholar
  22. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedGoogle Scholar
  23. Huff FJ, Mickel SF, Corkin S, Growdon JH (1988) Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Dev Res 12:271–278CrossRefGoogle Scholar
  24. Kopelman MD, Corn TH (1988) Cholinergic ‘blockade’ as a model for cholinergic depletion. Brain 111:1079–1110PubMedGoogle Scholar
  25. McGeer PL, McGeer EG, Suzuki J, Dolman CE, Nagai T (1984) Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 34:741–745PubMedGoogle Scholar
  26. Messerli P, Seron X, Tissto R (1979) Quelques aspects des troubles de la programmation dans le syndrome frontal. Arch Suisses de Neurol Neurochirurg Psychiatrie 125:23–25Google Scholar
  27. Mesulam M-M, Mufson EJ, Rogers J (1987) Age-related shrinkage of cortically projecting cholinergic neurons: a selected effect. Ann Neurol 22:31–36CrossRefPubMedGoogle Scholar
  28. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17:216–226CrossRefGoogle Scholar
  29. Nissen MJ, Knopman DS, Schacter DL (1987) Neurochemical dissociation of memory systems. Neurology 37:789–794PubMedGoogle Scholar
  30. Nordberg A, Winblad B (1981) Cholinergic receptors in human hippocampus — Regional distribution and variance with age. Life Sci 29:1937–1944CrossRefPubMedGoogle Scholar
  31. Overall JE, Beller SA (1984) The Brief Psychiatric Rating Scale (BRRS) in geropsychiatric research: I Factor structure on an inpatient unit. J Gerontol 39:187–193PubMedGoogle Scholar
  32. Parrott AC (1986) The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.Psychopharmacology 89:347–354Google Scholar
  33. Patel SV, Tariot PN (1991) Pharmacologic models of Alzheimer's disease. Psychiatr Clin N Am 14:287–308Google Scholar
  34. Petersen RC (1977) Scopolamine induced learning failures in man. Psychopharmacology 52:283–289CrossRefPubMedGoogle Scholar
  35. Ray PG, Meador KJ, Loring EW, Zamrini XH, Buccafusco JJ (1992) Central anticholinergic hypersensitivity in aging. J Geriatric Psychiatr Neurol 5:72–77Google Scholar
  36. Reitan RM, Wolfson D (1985) The Halstead-Reitan neuropsychological test battery: theory and application. Neuropsychological Press, TucsonGoogle Scholar
  37. Richardson JS, Miller PS, LeMay JS, Jyu CA, Neil SG, Kilduff CJ, Keegan DL (1985) Mental dysfunction and the blockade of muscarinic receptors in the brain of the normal elderly. Prog Neuropsychopharmacol Biol Psychiat 9:651–654CrossRefGoogle Scholar
  38. Rusted JM, Warburton DM (1988) The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 96:145–152Google Scholar
  39. Safer DJ, Allen RP (1971) The central effects of scopolamine in man. Biol Psychiatry 3:347–355PubMedGoogle Scholar
  40. Scinto LFM, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H (1994) A potential noninvasive neurobiological test for Alzheimer's disease. Science 266:1051–1054PubMedGoogle Scholar
  41. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 44:418–426PubMedGoogle Scholar
  42. Sunderland T, Tariot PN, Newhouse P (1988) Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 13:371–389CrossRefGoogle Scholar
  43. Troster AI, Beatty WW, Staton RD, Rorabaugh AG (1989) Effects of scopolamine on anterograde and remote memory in humans. Psychobiology 17:12–18Google Scholar
  44. Waugh NC, Barr RA (1980) Memory's mental tempo. In: Poon LW, Fozard JL, Cermak LS et al. (eds) New directions in memory and aging. Erlbaum, Hillsdale, NJ, pp 251–260Google Scholar
  45. Wechsler D (1981) Wechsler Adult intelligence scale — revised. Psychological Corporation, New YorkGoogle Scholar
  46. Wesnes K, Warburton DM (1983) Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9:154–157PubMedGoogle Scholar
  47. White P, Hilley CR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IE, Bowen DM (1977) Neocortical cholinergic neurons in the elderly people. Lancet 1:668–671CrossRefPubMedGoogle Scholar
  48. Yamamura HI (1981) Neurotransmitter receptor alterations in age-related disorders. In: Enna SJ, Samorajski T, Beer B (eds) Brain neurotransmitters and receptors in aging and age-related disorders, vol 17. Raven, New York, pp 143–147Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • P. N. Tariot
    • 1
    • 2
  • S. V. Patel
    • 1
    • 2
  • C. Cox
    • 3
  • R. E. Henderson
    • 4
  1. 1.Department of PsychiatryUniversity of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.Psychiatry UnitMonroe Community HospitalRochesterUSA
  3. 3.Department of BiostatisticsUniversity of Rochester School of Medicine and DentistryRochesterUSA
  4. 4.Department of Orthopaedics (Rehabilitation Medicine) and PsychiatryUniversity of Rochester School of MedicineRochesterUSA

Personalised recommendations